SGH to advance cancer treatment in new partnership

The collaboration will drive cord blood-derived allogeneic CAR T-cell development.

Singapore General Hospital (SGH) has entered an agreement with Charles River Laboratories International Inc. to drive the development of cord blood-derived allogeneic chimeric antigen receptor (CAR) T-cells for cancer treatment.

Under the agreement, SGH will use Charles River’s current good manufacturing practice-compliant master cell banking services for the critical starting materials for allogeneic CAR T-cells.

In addition, next-generation sequencing-based testing services will be used for cell line characterisation as part of SGH’s upcoming Phase I clinical trials.